Jamie Otfinoski, DPM
Podiatrist · Bethel, CTNPI 1083000269
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,275 of the $6,778 with a category attached, or 77.8%. 30 manufacturers reported payments, led by Smith+Nephew at 29.1% of the total. Reporting peaked in 2019 at $2,749 and has fallen 83.7% since, to $447 in 2025. Among podiatrist clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 178 payments — averaging $38.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$2K
- Gotham Surgical Solutions & Devices, Inc.$2K
- Organogenesis Inc.$506
- Averitas Pharma Inc.$472
- GRT US Holding, Inc.$300
- Stryker$229
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,27578%
- Education$1,50322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 62 | $1,975 |
| Gotham Surgical Solutions & Devices, Inc. | 4 | $1,678 |
| Organogenesis Inc. | 19 | $506 |
| Averitas Pharma Inc. | 20 | $472 |
| GRT US Holding, Inc. | 14 | $300 |
| Stryker | 7 | $229 |
| Osiris Therapeutics Inc. | 2 | $223 |
| Gramercy Extremity Orthopedics LLC | 1 | $178 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $131 |
| Convatec Inc. | 6 | $117 |
| Arthrex | 1 | $108 |
| Bioventus LLC | 5 | $97 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 5 | $96 |
| Paratek Pharmaceuticals, Inc. | 6 | $90 |
| Triad Life Sciences Inc. | 3 | $82 |
| Acell, Inc. | 2 | $59 |
| Merck | 3 | $53 |
| Nabriva Therapeutics, PLC | 3 | $53 |
| Treace Medical Concepts, Inc. | 1 | $50 |
| Melinta Therapeutics, LLC | 3 | $49 |
| Kerecis Limited | 1 | $39 |
| Paragon 28, Inc. | 1 | $31 |
| Sanara Medtech Inc. | 1 | $27 |
| KCI USA, Inc. | 1 | $25 |
| Integra Lifesciences Corporation | 1 | $24 |
| Medartis Inc. | 1 | $22 |
| Heron Therapeutics, Inc. | 1 | $20 |
| Amgen | 1 | $20 |
| Misonix Inc | 1 | $13 |
| Globus Medical | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,778 in reported general payments places this provider in the 90th percentile of 119 podiatrist providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JubliaEfinaconazole | 12 | $9,006 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 28 | $791 |
| Cephalexin | 19 | $761 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 19 | $102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia | $96 | $9,00612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 119 podiatrist providers in Connecticut.
Other podiatrist in Bethel
- Michael FeinBethel$9K
- Peter BlumeNew Haven$481K
- Robert DavisBridgeport$427K
- David NovickiMilford$67K
- Shane ReynoldsNorwalk$14K
- Eric LevineNorwich$12K
- Paul BetschartDanbury$10K
- Tehreem SajjadNew Britain$9K
- Christopher YardanWallingford$8K
- Devang PatelNorwalk$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.